{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:23:34Z","timestamp":1759335814152,"version":"3.44.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007366","name":"FISM","doi-asserted-by":"crossref","award":["FISM2012\/R\/9"],"award-info":[{"award-number":["FISM2012\/R\/9"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10072-025-08198-4","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:26:47Z","timestamp":1747787207000},"page":"4537-4546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Changes in circulating pro-inflammatory lymphocytes and cortical excitability with extended-interval natalizumab dosing in multiple sclerosis"],"prefix":"10.1007","volume":"46","author":[{"given":"Marco","family":"Pisa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Croese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria Dalla","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Congiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Gelibter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Orrico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9326-6753","authenticated-orcid":false,"given":"Letizia","family":"Leocani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"8","key":"8198_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","volume":"64","author":"GPA Rice","year":"2005","unstructured":"Rice GPA, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64(8):1336\u20131342. https:\/\/doi.org\/10.1212\/01.WNL.0000158329.30470.D0","journal-title":"Neurology"},{"issue":"6","key":"8198_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","volume":"91","author":"H Butzkueven","year":"2020","unstructured":"Butzkueven H, Kappos L, Wiendl H et al (2020) Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri observational program (TOP). J Neurol Neurosurg Psychiatry 91(6):660\u2013668. https:\/\/doi.org\/10.1136\/jnnp-2019-322326","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"8198_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","volume":"348","author":"DH Miller","year":"2003","unstructured":"Miller DH, Khan OA, Sheremata WA et al (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348(1):15\u201323. https:\/\/doi.org\/10.1056\/NEJMoa020696","journal-title":"N Engl J Med"},{"key":"8198_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","volume":"31","author":"JF Foley","year":"2019","unstructured":"Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR (2019) Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord 31:65\u201371. https:\/\/doi.org\/10.1016\/j.msard.2019.03.017","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"8198_CR5","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","volume":"95","author":"ZLE van Kempen","year":"2020","unstructured":"van Kempen ZLE, Hoogervorst ELJ, Wattjes MP et al (2020) Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. Neurology 95(6):e745\u2013e754. https:\/\/doi.org\/10.1212\/WNL.0000000000009995","journal-title":"Neurology"},{"issue":"8","key":"8198_CR6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","volume":"87","author":"L Zhovtis Ryerson","year":"2016","unstructured":"Zhovtis Ryerson L, Frohman TC, Foley J et al (2016) Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 87(8):885\u2013889. https:\/\/doi.org\/10.1136\/jnnp-2015-312940","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8198_CR7","doi-asserted-by":"publisher","first-page":"117385","DOI":"10.1016\/j.jns.2021.117385","volume":"424","author":"SF De Mercanti","year":"2021","unstructured":"De Mercanti SF, Signori A, Cordioli C et al (2021) MRI activity and extended interval of natalizumab dosing regimen: a multicentre Italian study. J Neurol Sci 424:117385. https:\/\/doi.org\/10.1016\/j.jns.2021.117385","journal-title":"J Neurol Sci"},{"issue":"7","key":"8198_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","volume":"21","author":"JF Foley","year":"2022","unstructured":"Foley JF, Defer G, Ryerson LZ et al (2022) Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 21(7):608\u2013619. https:\/\/doi.org\/10.1016\/S1474-4422(22)00143-0","journal-title":"Lancet Neurol"},{"issue":"2","key":"8198_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7224\/1537-2073.2013-017","volume":"16","author":"JN Ratchford","year":"2014","unstructured":"Ratchford JN, Brock-Simmons R, Augsburger A et al (2014) Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle. Int J MS Care 16(2):92\u201398. https:\/\/doi.org\/10.7224\/1537-2073.2013-017","journal-title":"Int J MS Care"},{"issue":"3","key":"8198_CR10","doi-asserted-by":"publisher","first-page":"e678","DOI":"10.1212\/NXI.0000000000000678","volume":"7","author":"GH Bringeland","year":"2020","unstructured":"Bringeland GH, Blaser N, Myhr KM, Vedeler CA, Gavasso S (2020) Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy. Neurol Neuroimmunol Neuroinflammation 7(3):e678. https:\/\/doi.org\/10.1212\/NXI.0000000000000678","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"8198_CR11","doi-asserted-by":"publisher","first-page":"117622","DOI":"10.1016\/j.jns.2021.117622","volume":"429","author":"GH Bringeland","year":"2021","unstructured":"Bringeland GH, Blaser N, Myhr KM, Vedeler CA, Gavasso S (2021) Wearing-off symptoms during standard and extended natalizumab dosing intervals: experiences from the COVID-19 pandemic. J Neurol Sci 429:117622. https:\/\/doi.org\/10.1016\/j.jns.2021.117622","journal-title":"J Neurol Sci"},{"issue":"1","key":"8198_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10072-013-1558-7","volume":"35","author":"B Goretti","year":"2014","unstructured":"Goretti B, Patti F, Cilia S et al (2014) The Rao\u2019s brief repeatable battery version B: normative values with age, education and gender corrections in an Italian population. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 35(1):79\u201382. https:\/\/doi.org\/10.1007\/s10072-013-1558-7","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"issue":"8","key":"8198_CR13","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1177\/1352458520960374","volume":"27","author":"M Pisa","year":"2021","unstructured":"Pisa M, Chieffo R, Congiu M et al (2021) Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 27(8):1222\u20131229. https:\/\/doi.org\/10.1177\/1352458520960374","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"7","key":"8198_CR14","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.clinph.2017.04.006","volume":"128","author":"M Stampanoni Bassi","year":"2017","unstructured":"Stampanoni Bassi M, Mori F, Buttari F et al (2017) Neurophysiology of synaptic functioning in multiple sclerosis. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 128(7):1148\u20131157. https:\/\/doi.org\/10.1016\/j.clinph.2017.04.006","journal-title":"Clin Neurophysiol Off J Int Fed Clin Neurophysiol"},{"issue":"3","key":"8198_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/1073858417717660","volume":"24","author":"V Di Lazzaro","year":"2018","unstructured":"Di Lazzaro V, Rothwell J, Capogna M (2018) Noninvasive stimulation of the human brain: activation of multiple cortical circuits. Neurosci Rev J Bringing Neurobiol Neurol Psychiatry 24(3):246\u2013260. https:\/\/doi.org\/10.1177\/1073858417717660","journal-title":"Neurosci Rev J Bringing Neurobiol Neurol Psychiatry"},{"issue":"4","key":"8198_CR16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.brs.2016.01.003","volume":"9","author":"JC Nantes","year":"2016","unstructured":"Nantes JC, Zhong J, Holmes SA, Narayanan S, Lapierre Y, Koski L (2016) Cortical damage and disability in multiple sclerosis: relation to intracortical Inhibition and facilitation. Brain Stimulat 9(4):566\u2013573. https:\/\/doi.org\/10.1016\/j.brs.2016.01.003","journal-title":"Brain Stimulat"},{"key":"8198_CR17","doi-asserted-by":"publisher","first-page":"108950","DOI":"10.1016\/j.jneumeth.2020.108950","volume":"346","author":"KE Hupfeld","year":"2020","unstructured":"Hupfeld KE, Swanson CW, Fling BW, Seidler RD (2020) TMS-induced silent periods: A review of methods and call for consistency. J Neurosci Methods 346:108950. https:\/\/doi.org\/10.1016\/j.jneumeth.2020.108950","journal-title":"J Neurosci Methods"},{"issue":"1","key":"8198_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/jnnp.74.1.123","volume":"74","author":"D Franciotta","year":"2003","unstructured":"Franciotta D, Zardini E, Bergamaschi R, Andreoni L, Cosi V (2003) Interferon gamma and Interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing Immunomodulatory treatment. J Neurol Neurosurg Psychiatry 74(1):123\u2013126. https:\/\/doi.org\/10.1136\/jnnp.74.1.123","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"8198_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jns.2013.05.023","volume":"331","author":"YC Learmonth","year":"2013","unstructured":"Learmonth YC, Dlugonski D, Pilutti LA, Sandroff BM, Klaren R, Motl RW (2013) Psychometric properties of the fatigue severity scale and the modified fatigue impact scale. J Neurol Sci 331(1):102\u2013107. https:\/\/doi.org\/10.1016\/j.jns.2013.05.023","journal-title":"J Neurol Sci"},{"issue":"1","key":"8198_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","volume":"83","author":"P O\u2019Connor","year":"2014","unstructured":"O\u2019Connor P, Goodman A, Kappos L et al (2014) Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology 83(1):78\u201386. https:\/\/doi.org\/10.1212\/WNL.0000000000000541","journal-title":"Neurology"},{"issue":"24","key":"8198_CR21","doi-asserted-by":"publisher","first-page":"e2989","DOI":"10.1212\/WNL.0000000000012084","volume":"96","author":"WZ Yeh","year":"2021","unstructured":"Yeh WZ, Widyastuti PA, Van der Walt A et al (2021) Natalizumab, Fingolimod and dimethyl fumarate use and Pregnancy-Related relapse and disability in women with multiple sclerosis. Neurology 96(24):e2989\u2013e3002. https:\/\/doi.org\/10.1212\/WNL.0000000000012084","journal-title":"Neurology"},{"issue":"17supplement2","key":"8198_CR22","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1212\/WNL.0000000000202006","volume":"100","author":"LZ Ryerson","year":"2023","unstructured":"Ryerson LZ, Foley J, Kister I et al (2023) Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) compared with Every-4-Week (Q4W) dosing: updated analysis of the TOUCH\u00ae prescribing program database (P14-3.011). Neurology 100(17supplement2):1598. https:\/\/doi.org\/10.1212\/WNL.0000000000202006","journal-title":"Neurology"},{"issue":"15","key":"8198_CR23","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","volume":"93","author":"LZ Ryerson","year":"2019","unstructured":"Ryerson LZ, Foley J, Chang I et al (2019) Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93(15):e1452\u2013e1462. https:\/\/doi.org\/10.1212\/WNL.0000000000008243","journal-title":"Neurology"},{"key":"8198_CR24","doi-asserted-by":"publisher","first-page":"135245852412609","DOI":"10.1177\/13524585241260977","volume":"14","author":"G Dalla Costa","year":"2024","unstructured":"Dalla Costa G, Leocani L, Pisa M et al (2024) Neuroaxonal damage in natalizumab-treated MS patients: the role of JCV antibody titres. Mult scler Houndmills Basingstoke engl. Published Online June 14:13524585241260977. https:\/\/doi.org\/10.1177\/13524585241260977","journal-title":"Published Online June"},{"issue":"22","key":"8198_CR25","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1212\/WNL.0b013e3181a8266f","volume":"72","author":"P Kivis\u00e4kk","year":"2009","unstructured":"Kivis\u00e4kk P, Healy BC, Viglietta V et al (2009) Natalizumab treatment is associated with peripheral sequestration of Proinflammatory T cells. Neurology 72(22):1922\u20131930. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a8266f","journal-title":"Neurology"},{"key":"8198_CR26","doi-asserted-by":"publisher","first-page":"102020","DOI":"10.1016\/j.msard.2020.102020","volume":"41","author":"D Cath\u00e9rine","year":"2020","unstructured":"Cath\u00e9rine D, Annelien DP, Anne S et al (2020) End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines? Mult Scler Relat Disord 41:102020. https:\/\/doi.org\/10.1016\/j.msard.2020.102020","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"8198_CR27","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1177\/1352458515621796","volume":"22","author":"F Mori","year":"2016","unstructured":"Mori F, Nistic\u00f2 R, Nicoletti CG et al (2016) RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 22(11):1405\u20131412. https:\/\/doi.org\/10.1177\/1352458515621796","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"11","key":"8198_CR28","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1177\/1352458512440207","volume":"18","author":"S Rossi","year":"2012","unstructured":"Rossi S, Studer V, Motta C et al (2012) Inflammation inhibits GABA transmission in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 18(11):1633\u20131635. https:\/\/doi.org\/10.1177\/1352458512440207","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"Pt A","key":"8198_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuropharm.2014.10.027","volume":"96","author":"A Vezzani","year":"2015","unstructured":"Vezzani A, Viviani B (2015) Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology 96(Pt A):70\u201382. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.10.027","journal-title":"Neuropharmacology"},{"issue":"6","key":"8198_CR30","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1136\/jnnp-2018-320050","volume":"90","author":"ZM Manjaly","year":"2019","unstructured":"Manjaly ZM, Harrison NA, Critchley HD et al (2019) Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry 90(6):642\u2013651. https:\/\/doi.org\/10.1136\/jnnp-2018-320050","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"8198_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrneurol.2015.222","volume":"11","author":"G Mandolesi","year":"2015","unstructured":"Mandolesi G, Gentile A, Musella A et al (2015) Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nat Rev Neurol 11(12):711\u2013724. https:\/\/doi.org\/10.1038\/nrneurol.2015.222","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"8198_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1191\/1352458505ms1163oa","volume":"11","author":"J Liepert","year":"2005","unstructured":"Liepert J, Mingers D, Heesen C, B\u00e4umer T, Weiller C (2005) Motor cortex excitability and fatigue in multiple sclerosis: a transcranial magnetic stimulation study. Mult Scler Houndmills Basingstoke Engl 11(3):316\u2013321. https:\/\/doi.org\/10.1191\/1352458505ms1163oa","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"5","key":"8198_CR33","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.clinph.2021.03.001","volume":"132","author":"V Versace","year":"2021","unstructured":"Versace V, Sebastianelli L, Ferrazzoli D et al (2021) Intracortical GABAergic dysfunction in patients with fatigue and dysexecutive syndrome after COVID-19. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 132(5):1138\u20131143. https:\/\/doi.org\/10.1016\/j.clinph.2021.03.001","journal-title":"Clin Neurophysiol Off J Int Fed Clin Neurophysiol"},{"issue":"13","key":"8198_CR34","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1177\/13524585221108080","volume":"28","author":"M Johnsson","year":"2022","unstructured":"Johnsson M, Farman HH, Blennow K et al (2022) No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab. Mult Scler Houndmills Basingstoke Engl 28(13):2070\u20132080. https:\/\/doi.org\/10.1177\/13524585221108080","journal-title":"Mult Scler Houndmills Basingstoke Engl"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08198-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:56:23Z","timestamp":1756364183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08198-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["8198"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08198-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was in agreement with the Declaration of Helsinki and was approved by the local Hospital Ethical Committee (N. 851\/DG). All the participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}